Halozyme Therapeutics Inc (HALO) — Quality & forensics
As of 2026-10-14 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 47
- Quality 94
- Growth 78
- Balance sheet 72
- Cash quality 64
- Capital allocation 61
- Momentum 97
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the HALO chart & overview · the earnings record
FAQ · from the current data · as of 2026-10-14
Quick answers
What is Halozyme Therapeutics Inc's Closelooknet quality reading?
The composite reads 74/100 across 7 modules, as of 2026-10-14: valuation 47, quality 94, growth 78, balance sheet 72, cash quality 64, capital allocation 61, momentum 97. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Halozyme Therapeutics Inc's Altman Z-Score?
4.99, which sits in the safe zone (above 2.99) as of 2026-10-14. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Halozyme Therapeutics Inc's Piotroski F-Score?
5 of 9, as of 2026-10-14. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Halozyme Therapeutics Inc's Beneish M-Score indicate?
-2.77 — below the −1.78 manipulation-risk threshold, as of 2026-10-14. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- KRYS Krystal Biotech Incindustry
- UCB.BR UCB SAindustry
- PTGX Protagonist Therapeutics Incindustry
- VRTX Vertex Pharmaceuticals Incindustry
- MRNA Moderna Incindustry
- DNA Ginkgo Bioworks Holdingsindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- CAI Caris Life Sciences, Inc. Common Stockindustry
- EXEL Exelixis Incindustry
- RXRX Recursion Pharmaceuticals Incindustry
- TWST Twist Bioscience Corpindustry
- TECH Bio-Techne Corpindustry
- RPRX Royalty Pharma Plcindustry
- ONC BeiGene, Ltd.industry
- REGN Regeneron Pharmaceuticals Incindustry
- RVMD Revolution Medicines Incindustry
- BION.SW BB Biotech AGindustry
- ROIV Roivant Sciences Ltdindustry